Total 2 articles
Daiichi Sankyo to invest $1.9 billion in ADC production facilities in the US, China, Germany, and Japan to mitigate geopolitical risks and tariff impact.
Daiichi Sankyo is investing $1.9 billion to expand cancer drug production in the U.S., China, Germany, and Japan, aiming to mitigate tariff risks and dominate the ADC market.
Advertise with Us
